<scp>MicroRNA</scp>‐326 negatively regulates <scp>CD155</scp> expression in lung adenocarcinoma

Nakanishi, Takayuki; Yoneshima, Yasuto; Okamura, Koji; Yanagihara, Toyoshi; Hashisako, Mikiko; Iwasaki, Takeshi; Haratake, Naoki; Mizusaki, Shun; Ota, Keiichi; Iwama, Eiji; Takenaka, Tomoyoshi; Tanaka, Kentaro; Yoshizumi, Tomoharu; Oda, Yoshinao; Okamoto, Isamu

doi:10.1111/cas.15921

Cited by 3 publications

(1 citation statement)

References 45 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This interaction is considered to be one of the ways through which resistance to PD-1 and PD-L1 inhibitors occurs. Consequently, miR-326 acts as a negative regulator of CD155 expression in lung adenocarcinoma, and as a result, it may have a role in the emergence of resistance to PD-1/PD-L1 inhibitors [ 181 ].…”

Section: Micrornas: Bridging the Gap Between Gene Regulation Immune C...mentioning

confidence: 99%

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

Zabeti Touchaei,

Vahidi

2024

Cancer Cell Int

View full text Add to dashboard Cite

Immunotherapy has revolutionized cancer treatment by harnessing the power of the immune system to eliminate tumors. Immune checkpoint inhibitors (ICIs) block negative regulatory signals that prevent T cells from attacking cancer cells. Two key ICIs target the PD-1/PD-L1 pathway, which includes programmed death-ligand 1 (PD-L1) and its receptor programmed death 1 (PD-1). Another ICI targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). While ICIs have demonstrated remarkable efficacy in various malignancies, only a subset of patients respond favorably. MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression, play a crucial role in modulating immune checkpoints, including PD-1/PD-L1 and CTLA-4. This review summarizes the latest advancements in immunotherapy, highlighting the therapeutic potential of targeting PD-1/PD-L1 and CTLA-4 immune checkpoints and the regulatory role of miRNAs in modulating these pathways. Consequently, understanding the complex interplay between miRNAs and immune checkpoints is essential for developing more effective and personalized immunotherapy strategies for cancer treatment. Graphical Abstract

show abstract

Section: Micrornas: Bridging the Gap Between Gene Regulation Immune C...mentioning

confidence: 99%

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

Zabeti Touchaei,

Vahidi

2024

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

A comprehensive in silico analysis and experimental validation of miRNAs capable of discriminating between lung adenocarcinoma and squamous cell carcinoma

Javanmardifard,

Rahmani,

Bayat

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

BackgroundAccurate differentiation between lung adenocarcinoma (AC) and lung squamous cell carcinoma (SCC) is crucial owing to their distinct therapeutic approaches. MicroRNAs (miRNAs) exhibit variable expression across subtypes, making them promising biomarkers for discrimination. This study aimed to identify miRNAs with robust discriminatory potential between AC and SCC and elucidate their clinical significance.MethodsMiRNA expression profiles for AC and SCC patients were obtained from The Cancer Genome Atlas (TCGA) database. Differential expression analysis and supervised machine learning methods (Support Vector Machine, Decision trees and Naïve Bayes) were employed. Clinical significance was assessed through receiver operating characteristic (ROC) curve analysis, survival analysis, and correlation with clinicopathological features. Validation was conducted using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Furthermore, signaling pathway and gene ontology enrichment analyses were conducted to unveil biological functions.ResultsFive miRNAs (miR-205-3p, miR-205-5p, miR-944, miR-375 and miR-326) emerged as potential discriminative markers. The combination of miR-944 and miR-326 yielded an impressive area under the curve of 0.985. RT-qPCR validation confirmed their biomarker potential. miR-326 and miR-375 were identified as prognostic factors in AC, while miR-326 and miR-944 correlated significantly with survival outcomes in SCC. Additionally, exploration of signaling pathways implicated their involvement in key pathways including PI3K-Akt, MAPK, FoxO, and Ras.ConclusionThis study enhances our understanding of miRNAs as discriminative markers between AC and SCC, shedding light on their role as prognostic indicators and their association with clinicopathological characteristics. Moreover, it highlights their potential involvement in signaling pathways crucial in non-small cell lung cancer pathogenesis.

show abstract

The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy

Murakami,

Ganguly

2024

Front. Immunol.

View full text Add to dashboard Cite

In recent years, immunotherapy has emerged as a crucial component of cancer treatment. However, its efficacy remains limited across various cancer types, highlighting unmet needs. Poliovirus receptor-related 2 (PVRL2) and Poliovirus receptor (PVR) are members of the Nectin and Nectin-like Molecules family, known for their role as cell-cell adhesion molecules. With the development of immunotherapy, their involvement in tumor immune mechanisms as immune checkpoint factors has garnered significant attention. PVRL2 and PVR are predominantly expressed on tumor cells and antigen-presenting cells, binding to PVRIG and TIGIT, respectively, which are primarily found on T and NK cells, thereby suppressing antitumor immunity. Notably, gynecological cancers such as ovarian and endometrial cancers exhibit high expression levels of PVRL2 and PVR, with similar trends observed in various other solid and hematologic tumors. Targeting these immune checkpoint pathways offers a promising therapeutic avenue, potentially in combination with existing treatments. However, the immunomodulatory mechanism involving these bindings, known as the DNAM-1 axis, is complex, underscoring the importance of understanding it for developing novel therapies. This article comprehensively reviews the immunomodulatory mechanisms centered on PVRL2 and PVR, elucidating their implications for various cancer types.

show abstract

MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma

Cited by 3 publications

References 45 publications

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways

A comprehensive in silico analysis and experimental validation of miRNAs capable of discriminating between lung adenocarcinoma and squamous cell carcinoma

The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy

Contact Info

Product

Resources

About